Conceptualization vs reality in periodontal therapy: genetic testing and host modulation.
This article addresses controversial issues associated with two different subjects: reliability of a genetic susceptibility test to identify individuals predisposed to developing periodontitis; use of subantimicrobial-dose doxycycline in the treatment of periodontal diseases. Each subject is assessed with regard to its practical application in the management of patients with chronic periodontitis.
Greenstein
Gary
G
Department of Periodontology, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA.
D000483:Alleles; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D018450:Disease Progression; D004318:Doxycycline / Q000627:therapeutic use*; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005884:Gingival Hemorrhage / Q000235:genetics / Q000628:therapy; D006801:Humans; D007375:Interleukin-1 / Q000235:genetics; D017622:Periodontal Attachment Loss / Q000235:genetics / Q000628:therapy; D010510:Periodontal Diseases / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D010514:Periodontal Pocket / Q000628:therapy; D010518:Periodontitis / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D007375:Interleukin-1; D004318:Doxycycline